4SC AG, of Martinsried, Germany, received U.S. Patent No. 7,176,241, which protects its drug candidate SC12267, a DHODH inhibitor for rheumatoid arthritis. The patent also covers backup substances related to SC12267, medical formulations and patient treatment with the drug.
Access Pharmaceuticals Inc., of Dallas, received a notice of allowance for its patent application, titled "Liquid Formulations for the Prevention and Treatment of Mucosal Diseases and Disorders." It provides protection for MuGard, the company's product for oral mucositis. The company also received U.S. Patent No. 7,166,733, titled "O,O'-Amidomalonato and N,O-Amidomalonato Platinum Complexes," which covers ProLindac and related tumor-targeted platinum compounds.
Acusphere Inc., of Watertown, Mass., received U.S. Patent 7,160,557 B2, titled "Matrices Formed of Polymer and Hydrophobic Compounds for Use in Drug Delivery." It covers the sustained drug release features of the company's porous microparticle formulations using a biodegradable shell material.
Adlyfe Inc., of Rockville, Md., was issued U.S. Patent No. 7,166,471, titled "Misfolded Protein Sensor Method in Body Fluids." It covers a method for rapid diagnostic testing of blood and other bodily fluids for the early detection of amyloid diseases.
Amazon Biotech Inc., of New York, was issued U.S. Patent No. 7,160,561, covering an herbal composition and method of treating HIV infection.
Aphios Corp., of Woburn, Mass., received U.S. Patent No. 7,147,802 B2, titled "Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein." It covers methods for manufacturing biodegradable polymer microspheres and nanospheres.
Applied NeuroSolutions Inc., of Vernon Hills, Ill., received U.S. Patent No. 7,161,060, titled "Transgenic Mice Comprising a Genomic Human Tau Transgene." The mice are designed for use as a model in Alzheimer's disease research.
Barrier Therapeutics Inc., of Princeton, N.J., received U.S. Patent No. 7,179,475, titled "Anhydrous Topical Skin Preparations," which covers a specific formulation of ketoconazole in a waterless gel that the company markets under the trade name Xolegel for seborrheic dermatitis.
BioE Inc., of St. Paul, Minn., received U.S. Patent 7,160,723, which provides protection for its cell separation compositions for isolating the company's Multi-Lineage Progenitor Cell stem cell.
BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., received a notice of allowance for a patent covering the formulation used in Elestrin (estradiol gel), the company's approved treatment for menopausal women.
BioSET Inc., of Rockville, Md., received U.S. Patent No. 7,166,574, titled "Synthetic Heparin-Binding Growth Factor Analogs," which describes fully synthetic peptide constructs that mimic the activity of human growth factors.
Chembio Diagnostics Inc., of New York, received a notice of allowance for the company's Dual Path Platform lateral flow rapid diagnostic test system.
ChemGenex Pharmaceuticals Ltd., of Melbourne, Australia, was granted U.S. Patent No. 7,169,774 B2, titled "Cephalotaxane Derivatives and Their Processes of Preparation and Purification." It covers the semisynthetic production of Ceflatonin (homoharringtonine) and its analogs and the use of those compounds in leukemia. Ceflatonin is partnered with Stragen Pharma SA, of Geneva.
Chromatin Inc., of Chicago, was granted U.S. Patent No. 7,119,250, titled "Plant centromere compositions." It permits construction of mini-chromosomes as vectors for plant and animal cells and includes techniques for creating transgenic plans using engineered mini-chromosomes.
Cylene Pharmaceuticals Inc., of San Diego, received a patent, titled "Substituted Quinobenzoxazine Analogs," which relates to ribosomal RNA biogenesis inhibition. The company also was issued a supporting patent, titled "Heterocyclic Substituted 1,4-Dihydro-4-Oxo-1,8-Naphthyridine Analogs," which covers potential backup compounds to Cylene's lead compound, CX-3543.
Digilab Inc., of Hannover, Germany, received a notice of allowance for Alzheimer's biomarkers discovered and identified with its Peptidomics technologies.
Enzo Biochem Inc., of New York, was granted two patents relating to labeling products for the genomics and diagnostics market: U.S. Patent No. 7,166,478, titled "Labeling Reagents and Labeled Targets, Target Labeling Processes and Other Processes for Using Same in Nucleic Acid Determinations and Analyses," and U.S. Patent No. 7,163,796, titled "Process for Detecting the Presence or Quantity of Enzymatic Activity in a Sample."
EvoGenix Ltd., of Sydney, Australia, received U.S. Patent No. 7,166,697, covering its development and use of Evibodies, small, antibody-like proteins that are one-tenth the size of an antibody and can be used as drugs or diagnostic agents.
Idera Pharmaceuticals Inc., of Cambridge, Mass., was issued U.S. Patent No. 7,176,296, titled "Modulation of Oligonucleotide CpG Mediated Immune Stimulation by Positional Modification of Oligonucleosides." It covers compounds comprising a synthetic immunostimulatory motif and an immunomodulatory moiety.
Immtech Pharmaceuticals Inc., of New York, was granted a patent, titled "Compounds, methods and compositions useful for the treatment of bovine viral diarrhea infection and hepatitis C virus infection."